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THE EFFECT OF RECALL PERIOD ON CANCER PATIENTS’ RATINGS OF
THE SEVERITY OF MULTIPLE SYMPTOMS
Shi Q1, Trask PC2, Wang S1, Mendoza T1, Cleeland C1
1University of Texas M. D. Anderson Cancer Center, Houston, TX, USA, 2Pﬁ zer, New London, 
CT, USA
In response to the US Food and Drug Administration’s concern on choice of suitable 
recall period for patient-reported outcomes (PRO), we examined the effects of recall
on symptom severity ratings by comparing ratings made using 24-hour and 7-day 
recall periods of the MD Anderson Symptom Inventory (MDASI). METHODS: Forty-
two patients at their 3rd to 8th week of chemoradiation in the Radiation Treatment 
Center at M.D. Anderson Cancer Center were asked to rate their symptoms using the
MDASI on two separate occasions, one week apart. At the initial visit, patients were
randomly assigned to rate their symptoms using either a 24-hour recall or a 7-day 
recall. On their next visit, patients were asked to rate their symptoms using the recall
period not used at their ﬁ rst visit. RESULTS: Correlation coefﬁ cients of global
symptom severity between 24-hour and 7-day recall periods were 0.89. Examining 
individual items, all correlation coefﬁ cients were over 0.7 except for distress (r  0.67).
The percentages of moderate to severe symptoms (5 or greater) were consistent in the 
24-hour and 7-day recall periods, with no signiﬁ cant difference in the prevalence of 
moderate to severe symptoms being found between the two recall periods. Cronbach 
á coefﬁ cients in both 24-hour and 7-day recalls were all over 0.8. Symptoms from 
both recall periods were more severe for patients with poorer performance status. 
Among 20 patients who underwent cognitive debrieﬁ ng, 70% thought the 7-day recall 
was “more appropriate” for answering the MDASI, but 85% did not think that recall 
period would inﬂ uence their answers. CONCLUSIONS: This study demonstrated that
a 7-day recall version of the MDASI has psychometric properties consistent with the 
24-hour recall version, which may allow its use in future clinical trials. In addition, 
this study may help ease the choice of recall period when symptoms are outcome
measures.
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RELATIONSHIP BETWEEN QUALITY OF LIFE AND HEALTH-RELATED 
MEASURES INCLUDING SYMPTOMS, BIOCHEMICAL MARKERS AND
TUMOR BURDEN
Vinik EJ, Vinik AI, Silva MP
Eastern Virginia Medical School, Norfolk, VA, USA
OBJECTIVES: Examine the relationship of quality of life measures in neuroendocrine 
tumor patients using the Norfolk QOL-NET by correlating the total questionnaire 
score with each of the Norfolk QOL-NET domains, with tumor burden, biochemical 
status and the Norfolk Carcinoid Symptom Score tool. METHODS: During their
visits to the Neuroendocrine Unit at Eastern Virginia Medical School, 29 adult 
patients diagnosed with neuroendocrine tumor(s) signed the consent form and com-
pleted the Norfolk QOL-NET. Data related to current tumor burden, biochemical
status and the validated Carcinoid Symptom Score was obtained from their ﬁ les 
matching the date they completed the questionnaires. RESULTS: The Norfolk QOL-
NET total score correlated positively with all of its domains – physical functioning 
(r  0.96, p  0.0001), depression(r  0.73, p  0.001), gastrointestinal (r  0.78,
p  0.001), ﬂ ushing (r  0.62, p  0.0003), respiratory (r  0.65, p  0.0002), positive 
attitude (r  0.52, p  0.004), and cardiovascular (r  0.46, p  0.012); with the 
Norfolk Carcinoid Symptom Score (r  0.6, p  .0001); with tumor burden (r  0.52,
p  0.004), and serotonin (r  0.62, p  0.013). Serotonin was the only biochemical 
marker that correlated positively with a poor quality of life in patients with neuroen-
docrine tumors. CONCLUSIONS: We demonstrated a strong correlation between 
Norfolk QOL-NET and symptoms, biochemical markers and tumor burden. Norfolk 
QOL-NET seems sensitive to symptom change, physical functioning, respiratory and 
cardiovascular disease progression or remission. Norfolk QOL-NET should be an
important tool for measuring patients’ perception of the burden of their disease, relat-
ing to the tumor burden and the biochemical abnormality as well as the impact of 
treatment modalities. The Norfolk quality of life tool may also be a useful guide in 
deciding changes in therapy to alter apparent health status as well as an endpoint in
clinical studies.
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TEST-RETEST RELIABILITY OF THE EQ-5D VISUAL ANALOG SCALE 
ACROSS POPULATIONS AND CONDITIONS
Wilke CT1, Pickard AS2
1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, University of Illinois
at Chicago, Chicago, IL, USA
OBJECTIVES: As electronic versions of HRQL measures such as the EQ-5D become 
available, it is important to understand the reliability of different modes of technology. 
The aim of this study was to summarize the evidence of test-retest reliability for the
EQ-5D visual analog scale (VAS), a scale ranging from 0 (worst imaginable health) to 
100 (best imaginable health). METHODS: A structured literature search was con-
ducted in MEDLINE using keywords relevant to EQ-5D, visual analog scales, and
test-retest reliability. Original research studies that reported information on the test-
retest reliability of the EQ-5D VAS were included. Demographic characteristics, inter-
val between observations, and intraclass correlation coefﬁ cients (ICCs) were abstracted. 
RESULTS: Of the 25 studies that examined test-retest reliability of EQ-5D, 14 
reported evidence of test-retest reliability for EQ-5D VAS. Most of the papers were
studies that assessed the validity of EQ-5D for certain countries or languages (n 
5/14, 36%) or for use in patient groups / certain medical conditions (n  7/14, 50%). 
The most common interval between observations was 2 weeks (n  4/14, 29%), with 
analyses conducted on a subgroup of self-reported stable patients, based on self-report,
in 4 studies. TRT ICCs ranged from ICC  0.38 for Alzheimer’s patients to ICC 
0.90 (95% CI: 0.88–0.92) for a methodological study conducted in Spain, with a 
median ICC  0.8 across the 14 studies. Almost 80% of studies (11/14) reported ICCs 
above 0.7, a reliability threshold considered acceptable at the group level. CONCLU-
SIONS: EQ-5D VAS demonstrated acceptable TRT reliability in most studies of popu-
lations and medical conditions except in Alzheimer’s disease, where proxies but not 
patients provided reproducible assessments.
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PSYCHOMETRIC ASSESSMENT OF AN INSTRUMENT TO MEASURE
PATIENT SATISFACTION WITH MEDICATION THERAPY MANAGEMENT
SERVICES
Bodhani A1, West D2, Li C1, Ounpraseuth S1, Pace A1
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Mississippi
School of Pharmacy, University, MS, USA
OBJECTIVES: To adapt a pharmaceutical care satisfaction instrument and pilot 
test it to measure patient satisfaction with Medication Therapy Management (MTM) 
services. METHODS: A questionnaire was mailed to Medicare Part D beneﬁ ciaries 
who received face-to-face MTM services in a retail pharmacy in a southern state. The
questionnaire consisted 23 questions addressing patients’ perceptions, experience, and
satisfaction related to MTM services. Information regarding patients’ satisfaction was
gathered using an instrument developed by Gourley et al. (2001) with a few modiﬁ ca-
tions to make it applicable to MTM service encounter. We assessed the content validity
and pre-tested the questionnaire to determine the time needed to complete and to
ensure item clarity. Factor analysis using the principal component method with
varimax rotation and reliability analysis using Cronbach’s alpha was conducted. 
RESULTS: Of the 403 successfully mailed surveys; we received 122 useable surveys 
yielding a response rate of 30.27%. Sample comprised 55% females, 68% whites. 
Over 80% of the study participants took 5–16 unique medications daily. Factor analy-
sis using a 0.55 cut-off for factor loading yielded four factors that accounted for 
64.4% of the variance. Reliability assessment resulted in Cronbach’s alpha value of 
0.941 for the entire scale, 0.904 for factor 1 (Managing Medication Therapy), 0.917
for factor 2 (Patient Education), 0.910 for factor 3 (Overall Satisfaction), and 0.841 
for factor 4 (Pharmacist-Patient Relationship). The overall mean score was found to 
be 4.5/5 indicating that the participants were satisﬁ ed with the MTM services they 
received. CONCLUSIONS: The adapted questionnaire consisted of four subscales
similar to subscales found in other pharmacy satisfaction surveys. The instrument 
appears to be useful in measuring patient satisfaction with MTM services received in 
a pharmacy. Low sample size, extrapolation of results to other states and settings, and
recall bias are the notable limitations associated with this study.
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DETERMINING THE MINIMALLY IMPORTANT DIFFERENCES OF FOUR
PREFERENCE-BASED HEALTH INDICES: A SIMULATION APPROACH
Luo N1, Johnson JA2, Coons SJ3
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OBJECTIVES: To estimate the minimally important differences (MIDs) for the EQ-
5D, HUI2, HUI3, and SF-6D health index scores using health-state transitions 
described by each instrument’s health classiﬁ cation systems as anchors. METHODS:
We assume that the smallest differences in health states deﬁ ned by each instrument’s 
multi-attribute health classiﬁ cation (MAHC) systems are associated with important 
differences in health preferences. Based on this assumption, the MID was deﬁ ned as 
the difference in index score between two health states deﬁ ned by each MAHC system 
differing in only one health dimension or attribute and by only one functional level.
Thus, for each instrument, we enumerated all the theoretically possible pairs of mini-
mally different health states and calculated the differences in index scores for those 
pairs of health states. RESULTS: Based on our deﬁ nitions, the total number of pairs 
of minimally different health states is 405 for the EQ-5D, 127,600 for the HUI2, 
6,382,800 for the HUI3, and 86,700 for the SF-6D. The mean (standard deviation) 
MID estimate was 0.040 (0.026) for the EQ-5D (US algorithm), 0.082 (0.032) for the
EQ-5D (UK algorithm), 0.045 (0.039) for the HUI2, 0.032 (0.027) for the HUI3, and
0.027 (0.028) for the SF-6D. The effect sizes corresponding to these MID estimates 
range from 0.19 to 0.28. In general, these MID estimates are quite comparable to 
those estimated using other anchor-based methods. CONCLUSIONS: This new 
approach to estimating the MIDs of four commonly used preference-based HRQoL 
index scores provides new and useful information for identifying and interpreting 
meaningful change (or differences) in scores.
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MEASURING POPULATION HEALTH STATUS USING EQ-5D: 
RESULTS FROM THE HEALTH SURVEY FOR ENGLAND 1996–2006
Zarate V1, Kind P2
1University of York, York, North Yorkshire, UK, 2University of York, York, UK
OBJECTIVES: The development of national health policies requires a clear under-
standing about how objective and subjective measures of health status vary over time.
This task is only possible when generic self-reported instruments are considered part 
of population surveys alongside traditional health indicators. This study examines 
variations in self-reported health status in England as measured by the EuroQol EQ-5D 
